Publications
Specialty
Search
Wound Care
08/26/2024
Stability Biologics initiated a 324-patient study to evaluate AmnioCore, Amnio Quad-Core + SoC vs SoC alone in management of DFU and VLU. Primary outcome measures the proportion of pts achieving complete closure at 1-12 weeks. Estimated study completion 8/26. clinicaltrials.gov
Wound Care
08/26/2024
Coloplast shared that a new RCT comparing the performance of Kerecis fish skin to the standard of care in the treatment of complex DFUs is pending publication. This is the largest Kerecis study to date, with a sample size of more than 250 patients. CLPBF Q3FY24 Earnings Transcript
Wound Care
08/26/2024
A 240-patient study found that 84.2% of patients receiving prone positioning ventilatory therapy developed PUs. A multidisciplinary approach is crucial for preventing and managing PUs, which are often avoidable. JWC
Wound Care
08/26/2024
KeriCure received 510(k) clearance for its Field Shield Wound Dressing, a spray-on hydrogel wound dressing that hydrates, seals and protects dermal injuries to create and maintain a moist wound environment. The device contains silver hydrosol.
Podiatry Today
08/26/2024
Dr. Cole shares highlights from her recent research poster.
Journal of Clinical Pathways
08/26/2024
Matthew Cortese, MD, discusses recent updates in the National Comprehensive Cancer Network guidelines for the treatment of chronic lymphocytic leukemia (CLL) and ongoing clinical trials in this space.
Oncology
08/26/2024
According to results from a phase 2/3 study, bevacizumab-erlotinib switch maintenance improved progression-free survival among patients with chemotherapy-responsive advanced biliary tract cancers.
Wounds
08/26/2024
The current review explores the mechanisms by which fish skin can boost the wound healing process.
Psych Congress Network
08/26/2024
Holiday stress is among the top 10 topics women with ADHD post about.
Journal of Invasive Cardiology, CardioVascular
08/26/2024
The authors share their institutional experience with the Perclose post-closure technique for vascular access closure after Impella removal.
First Report Managed Care
08/26/2024
Follicular regulatory T cells (Tfr) are a potential target in treating follicular lymphoma (FL), the most common indolent B-cell lymphoma, according to study results published in Frontiers in Immunology.
ePlasty, Surgery
08/26/2024
This study compares scaphoid waist fracture treatments, analyzing union rates and complications between nitinol staples and headless compression screws.
Podiatry Today
08/26/2024
The authors of a recent study pointed out that much of the data on alcohol consumption and gout risk either combined the sexes in their cohort or mostly studied men. They set out to look more closely at each sex and their incidence of gout in relation to total and specific alcohol consumption.
Psych Congress Network
08/26/2024
Women 20 and older are the most prescribed segment for ADHD treatment with a nonstimulant.
Psych Congress Network
08/26/2024
Rates of most mental illnesses were higher over the 4 weeks after a COVID-19 diagnosis compared with before or without COVID-19, according to cohort study results published in JAMA Psychiatry.
Oncology, Journal of Clinical Pathways
08/26/2024
Kathleen Moore, MD, discusses the current treatment landscape for patients with advanced and recurrent endometrial cancer, considering the recent expanded indication of dostarlimab plus chemotherapy.
Pharmacy Learning Network
08/26/2024
A combination of bioinformatics analysis and nanomaterial optimization improves the sensitivity, specificity, and detection rate of viral diagnosis of respiratory viruses, according to a study published in Frontiers and Biotechnology.
EP Lab Digest
08/26/2024
Expanded indication based on an abundance of clinical evidence for AtriClip Devices
EP Lab Digest
08/26/2024
Risk Predication Tool, Developed by Anesthesiologists at Montefiore Health System and Albert Einstein College Medicine, May Reduce Adverse Outcomes
EP Lab Digest
08/26/2024
New analyses, including presentations on CAMZYOS® (mavacamten), ELIQUIS® (apixaban) and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases